Pristine Bioproduction: About Us.
Pristine Bioproduction is the brainchild of the founder Timothy Matthews. After spending years at Genentech watching the development of new drugs from the "inside", Tim decided to take his significant technical skills, his industry experience, and his drive to continuously improve processes outside of the big company framework and focus on the specific problem of decreasing cost and increasing efficiency of the production of bulk biological drugs such as monoclonal antibodies for pre-clinical GLP studies. Pristine uses state of the art single-use equipment to lower production costs and maximize flexibility and nimbleness.
Timothy Matthews, CEO and Founder
Until very recently, Tim was a Senior Engineer/Group Leader in Process Development Engineering at Genentech. Tim stepped away from Genentech to focus on founding a CMO based on disposable processing technologies. Prior to working at Genentech, Tim graduated from Penn State University in 1996 with a degree in Biochemical Engineering and a minor in Environmental Engineering.
Tim came to Genentech to work in Purification process development. In that role Tim performed process development in chromatography, centrifugation and UF/DF formulation. Tim also developed a novel protein crystallization process for purification of a coli derived therapeutic protein. Tim served as Implementation Team leader for various clinical manufacturing campaigns for this molecule.
In 2003, Tim transitioned into a new technology development role in PD Engineering where he has focused heavily on testing and implementation of single-use processing equipment. Tim held the position of the global Single Use Technology Team (SUTT) Leader at Genentech/Roche where he focused on supply chain management and coordination of best practices for single-use technology implementation.
Peter Latham, Advisor
Peter Latham has twenty years in general management and thirteen years in financial, strategic and business development consulting to the biotech industry. As founder and president of New Venture Advisors, Inc., then BioPharm Services, Inc. (which became Latham BioPharm Group), Mr. Latham has worked with a variety of companies ranging from large pharmaceutical companies to biotechs, venture capitalists and start-up entities. He has served as Acting President and on a variety of boards for clients ranging from start-ups to publicly traded companies. Prior to this, Mr. Latham was V.P. Engineering and Licensing for Drug Delivery Development, Inc. (DDD) where he managed the US operations and negotiated several large licenses for a drug delivery firm based in France. Prior to DDD, Mr. Latham was Subsystem Manager at McDonnell Douglas responsible for all of the cargo handling systems and interiors on the USAF C-17 program.
Mr. Latham holds a B.S. in Mechanical Engineering from Rensselaer Polytechnic Institute and an M.S. in Management from Massachusetts Institute of Technology's Sloan School. He was managing editor of Bioprocess News, has published in multiple industry journals and chairs, advises and presents regularly at industry conferences.
Susan Dexter, Advisor
Susan Dexter has over 25 years of experience in biotechnology science and business development. Ms. Dexter worked as a scientist doing cell culture and small scale manufacturing, before moving into the business of science and selling biotechnology contract manufacturing services ranging from process development through commercial manufacturing, and CMC related services. Ms. Dexter has supported multiple start-up companies as well as established biotech, pharmaceutical and technology companies, performing strategic business development, M&A , and technology in- and out-licensing. Prior to joining Latham Biopharm Group, Ms. Dexter was Chief Business Officer at Xcellerex, Inc. responsible for all aspects of business development for contract manufacturing services (CMO), and the sale of disposable technologies and integrated modular manufacturing facilities (FlexFactory®). Prior to Xcellerex, Ms. Dexter was the VP of Business Development at The Dow Chemical Company after developing a $7.0M CMO business at the Collaborative BioAlliance, and then selling it to Dow.She was also the Assoc. Director of Business Development (and was the first US employee) of Celltech, then Lonza, where she identified and closed commercial supply agreements in excess of $650M and negotiated over 20 gene expression technology licenses worth over $250M.
Susan holds a double major with Honors in Immunology and Marketing from American University, Washington, D.C., a graduate of the 'Negotiation for Lawyers" course, Harvard University; Ms. Dexter also lectures annually at University College London (credit course) and presents annually at a variety of industry conferences.